This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Ligand Pharmaceuticals, Inc.
Drug Names(s): alitretinoin, Oral ALRT1057, Oral LGD1057
Description: Panretin capsules contain alitretinoin, which is a naturally-occurring endogenous retinoid that binds to and activates all known intracellular retinoid receptor subtypes (RARa, RARb, RARg, RXRa, RXRb and RXRg). Once activated, these receptors function as transcription factors that regulate the expression of genes that control the process of cellular differentiation and proliferation in both normal and neoplastic cells. Alitretinoin inhibits the growth of Kaposi’s sarcoma (KS) cells in vitro.
Deal Structure: In March 1999, Ligand signed marketing and distribution agreements with Ferrer Internacional, S.A. to exclusively market and distribute ONTAK, Panretin gel, Panretin capsules, Targretin gel and Targretin capsules, in Spain, Portugal, Greece, and Central and South America.
In January 2000, Ligand signed a marketing and distribution agreement with Alfa Wassermann S.p.A. to exclusively market and distribute in Italy ONTAK, Panretin gel, Panretin capsules, Targretin gel and Targretin capsules. Ligand received from Alfa Wassermann, as reimbursement for certain registration services previously incurred by Ligand for the products, $0.75 million upon signing and will receive additional amounts aggregating up to $1.0 million upon achievement of certain milestones. Under the terms of the agreement, Alfa Wassermann will have exclusive long-term marketing and distribution rights and responsibilities in Italy for ONTAK, Panretin gel, Panretin capsules, Targretin gel and Targretin capsules....See full deal structure in Biomedtracker
Partners: Perrigo Company PLC Grupo Ferrer Internacional, S.A. Alfa Wassermann SpA
Panretin capsules News
Additional information available to subscribers only: